This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Amunix Pharmaceuticals, Inc. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Mika Derynck: Innovator in Bispecific Antibody Technology
Introduction
Mika Derynck is a prominent inventor based in South San Francisco, CA. She has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibody constructs. Her innovative work has the potential to advance therapeutic strategies in various medical applications.
Latest Patents
Mika Derynck holds a patent for "HER-2 targeted bispecific compositions and methods for making and using the same." This patent discloses polypeptides and methods that involve a bispecific antibody construct covalently linked to an extended recombinant polypeptide. The design includes a barcode fragment that can be released upon protease digestion, along with a Release Segment that allows for the proteolytic cleavage of the bispecific antibody construct from the polypeptide.
Career Highlights
Mika is currently associated with Amunix Pharmaceuticals, Inc., where she continues to push the boundaries of biopharmaceutical innovation. Her work focuses on creating advanced therapeutic solutions that can improve patient outcomes in cancer treatment and other diseases.
Collaborations
Mika collaborates with notable colleagues such as Volker Schellenberger and Eric Johansen, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Mika Derynck's contributions to bispecific antibody technology exemplify her commitment to advancing medical science. Her innovative patent and collaborative efforts position her as a key figure in the biotechnology industry.